EX-99.1 2 ea022549401ex99-1_renalytix.htm PRESS RELEASE

Exhibit 99.1

 

 

Renalytix plc

(“Renalytix” or the “Company”)

 

Result of AGM

 

LONDON and NEW YORK, 19 December 2024 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, announces that at the Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed.

 

The results of the AGM are detailed below:

 

   For   % voted
in favour		   Against   % voted
against		   Withheld 
Ordinary resolutions                    
1 Receive and adopt the UK 2024 Annual Report   215,649,238    99.86%   298,365    0.14%   40,760 
2 Approve Directors’ Remuneration Report   187,117,898    86.76%   28,544,007    13.24%   326,458 
3 Ratify the selection of CohnReznick   215,624,372    99.92%   178,413    0.08%   185,578 
4 Reappoint PKF Littlejohn LLP as Auditors   215,760,810    99.91%   184,281    0.09%   43,272 
5 Authorise Board to determine auditors’ remuneration   215,474,022    99.86%   302,821    0.14%   211,520 
6 Authorise the issue of shares under the 2020 Equity Incentive Plan with Non-Employee Sub-Plan   151,371,930    83.99%   28,863,246    16.01%   35,753,187 
7 Authorise the Issue of Equity   151,554,272    83.99%   28,898,602    16.01%   35,535,489 
                          
Special resolutions                         
8 Authorise Issue of Equity without Pre-emptive Rights   151,648,214    84.04%   28,799,536    15.96%   35,540,613 
9 Authorise Market Purchase of Ordinary Shares   180,179,511    99.83%   305,940    0.17%   35,502,912 

 

For further information, please contact:

 

Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
   
Stifel (Nominated Adviser and Joint Broker) Tel: 020 7710 7600
Nicholas Moore / Nick Harland / Ben Good  
   
Oberon Capital (Joint Broker) Tel: 020 3179 5300
Mike Seabrook / Nick Lovering  
   
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
   
CapComm Partners  
Peter DeNardo Tel: 415-389-6400 or [email protected]

 

About Renalytix (www.renalytix.com)

 

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient’s risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

 

The over 10,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).